胃と腸53巻5号

2018年05月発行

増刊号 早期胃癌2018

ノート

胃癌遺伝子検査の現状と未来

著者： 永塚真¹ 杉本亮¹ 藤田泰子¹ 刑部光正¹ 上杉憲幸¹ 石田和之¹ 菅井有¹

所属機関： ¹岩手医科大学医学部病理診断学講座

ページ範囲：P.783 - P.788

文献概要

要旨●胃癌における分子異常の解析が進み，その腫瘍発生が明らかになった．胃癌は4つの分子異常に類型化され〔①CIN（chromosomal instability），②MSI（microsatellite instability），③GS（genomically stable），④EBV（Epstein-Barr virus-related cancer）〕，組織型との関連性も指摘される．また，分子異常を標的とする分子標的薬と分子異常を検索する方法であるコンパニオン診断の開発が進んできた．HER2発現はトラスツズマブ投与において重要な役割を担い，PD-1，PD-L1は胃癌の新しい分子ターゲットとなりうる．

参考文献

1）Sugai T, Sugimoto R, Habano W, et al. Genetic differences stratified by PCR-based microsatellite analysis in gastric intramucosal neoplasia. Gastric Cancer　20：286-296, 2017

2）Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. Nature　513：202-209, 2014

3）Yu Y. Molecular classification and precision therapy of cancer：immune checkpoint inhibitors. Front Med　2017［Epub ahead of print］

4）Ichikawa H, Nagahashi M, Shimada Y, et al. Actionable gene-based classification toward precision medicine in gastric cancer. Genome Med　9：93, 2017

5）Sugai T, Eizuka M, Arakawa N, et al. Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status. Gastric Cancer　2018［Epub ahead of print］

6）Sugai T, Habano W, Jiao YF, et al. Analysis of genetic alterations associated with DNA diploidy, aneuploidy and multiploidy in gastric cancers. Oncology　68：548-557, 2005

7）Sugimoto R, Sugai T, Habano W, et al. Clinicopathological and molecular alterations in early gastric cancers with the microsatellite instability-high phenotype. Int J Cancer　138：1689-1697, 2016

8）Akiba S, Koriyama C, Herrera-Goepfert R, et al. Epstein-Barr virus associated gastric carcinoma：epidemiological and clinicopathological features. Cancer Sci　99：195-201, 2008

9）Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer：correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science　235：177-182, 1987

10）Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med　344：783-792, 2001

11）Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase 3, open-label, randomised controlled trial. Lancet　376：687-697, 2010

12）日本病理学会（編）胃癌・乳癌HER2病理診断ガイドライン．金原出版，2015

13）Okazaki T, Chikuma S, Iwai Y, et al. A rheostat for immune responses：the unique properties of PD-1 and their advantages for clinical application. Nat Immunol　14：1212-1218, 2013

14）Xing X, Guo J, Wen X, et al. Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology　21：e1356144, 2017

15）Gu L, Chen M, Guo D, et al. PD-L1 and gastric cancer prognosis：A systematic review and meta-analysis. PLoS One　12：e0182692, 2017

16）Tartari F, Santoni M, Burattini L, et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients：Recent insights and future challenges. Cancer Treat Rev　48：20-24, 2016